By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Biogen Idec, Inc. (Massachusetts) 

14 Cambridge Center

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-679-2000 Fax: 617-679-2617


SEARCH JOBS
Biogen Idec (NASDAQ: BIIB) is a biotechnology leader that discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hemophilia and autoimmune disorders. With its rich scientific heritage and passionate commitment to pioneering new advances, Biogen Idec recognizes that cutting-edge science and medicines can address unmet patient needs to change the course of devastating diseases.

Founded in 1978, Biogen Idec is the world’s oldest independent biotechnology company. Patients worldwide benefit from its leading multiple sclerosis therapies, and the company generates nearly $5 billion in annual revenues. Biogen Idec has a strong late stage pipeline with the potential to launch new products for multiple sclerosis, amyotrophic lateral sclerosis (ALS) and hemophilia by 2015.

With about 4,800 employees worldwide, Biogen Idec is a truly global organization. In addition to our headquarters in Weston, Mass., and our research operations in Cambridge, Mass., we have a world-class manufacturing facility in North Carolina and offices in Canada, Australia, Japan and throughout Europe. We also have a direct commercial presence in more than 29 markets and a network of distribution partners in more than 70 additional markets, including new markets such as Central/Eastern Europe, Brazil, China and India.

For product labeling, press releases and additional information about the company, please visit www.biogenidec.com


Key Statistics


Email:
Ownership: Public

Web Site: Biogen Idec, Inc. (Massachusetts)
Employees: 1700
Symbol: BIIB
 



Industry
Biotechnology


Collaborations

NeoGenesis Pharmaceuticals, Inc.  Small molecule High Throughput Screening for multiple programs (6/01)

GPC Biotech, Inc.  HIV TAT-derived transport polytptides and methods of their use (5/01) - this was an outlicense from a research

ICOS Corporation  LFA-1 small molecule for psoriasis (7/01)

Elan Corporation PLC  (crohn's & MS)

Dyax Corp.  Antibody phage display





Company News
Novartis AG (NVS) Follows Biogen Idec, Inc. (Massachusetts) (BIIB), GlaxoSmithKline (GSK)'s Footsteps With New State Of The Art Offices; Space Reflects "The Novartis Way Of Working" 8/29/2014 6:05:51 AM
Biogen Idec, Inc. (Massachusetts) (BIIB) In Panel At The Citi 9th Annual Biotech Conference 8/27/2014 9:03:27 AM
Biogen Idec, Inc. (Massachusetts) (BIIB) Release: Health Canada Approves Eloctate™, The First Therapy To Extend The Interval Between Prophylactic Infusions In Hemophilia A 8/26/2014 8:29:14 AM
Biogen Idec, Inc. (Massachusetts) (BIIB) Poaches Renowned Neurologist From Novartis AG (NVS) To Lead ALS Innovation Hub 8/26/2014 6:10:40 AM
Biogen Idec, Inc. (Massachusetts) (BIIB) Names Adriana Karaboutis EVP, Technology And Business Solutions 8/21/2014 8:35:47 AM
FDA Approves Biogen Idec, Inc. (Massachusetts) (BIIB)'s Multiple Sclerosis Drug Plegridy 8/18/2014 6:10:52 AM
Shares Of Biogen Idec, Inc. (Massachusetts) (BIIB) Slip As Tecfidera Hits Second Hurdle In Germany 8/4/2014 6:31:47 AM
Proteostasis Therapeutics, Inc. Announces Achievement Of Preclinical Milestone In Neurodegenerative Diseases Collaboration With Biogen Idec, Inc. (Massachusetts) (BIIB) 7/30/2014 11:22:07 AM
Biogen Idec, Inc. (Massachusetts) (BIIB) Release: PLEGRIDY™ (Peginterferon beta-1a) Approved In The European Union For The Treatment Of Multiple Sclerosis 7/24/2014 11:55:22 AM
Biogen Idec, Inc. (Massachusetts) (BIIB) And Yahoo! Inc. (YHOO) Health Spotlight Visionaries Whose Work Benefits People With Multiple Sclerosis (MS) 7/16/2014 9:05:19 AM
12345678910...
//-->